Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

Wang, Jie; Lü, Shun; Yu, Xinmin; Hu, Yanping; Sun, Yuping; Wang, Zhijie; Zhao, Jun; Yu, Yan; Hu, Chunhong; Yang, Kunyu; Feng, Guosheng; Ying, Kejing; Zhuang, Wu; Zhou, Jianying; Wu, Jingxun; Jiin Leaw, Shiang; Zhang, Jing; Lin, Xiao; Liang, Liang; Yang, Nong

doi:10.1001/jamaoncol.2021.0366

Public

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

Published in JAMA Oncology • Apr 1, 2021

Authors:

Jie Wang

Shun Lü

Xinmin Yu

Abstract

IMPORTANCE: This study demonstrates that tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS) in patients with advanced squamous non-small-cell lung cancer (sq-NSCLC). OBJECTIVE: To assess the efficacy and safety/tolerability of tislelizumab plus ...

Subject

Medicine

Carboplatin

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!